Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors

Summary

The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor activity of GEN1056. GEN1056 will be studied in patients with advanced or metastatic solid cancer, for whom standard of care (SOC) therapy is not an option. All participants will get GEN1056.

Timeline

Start

2022-10-24

Primary completion

2025-10-23

Completion

2025-10-23

Drugs

Indications